Revenue: As of FY2027 Q1, the actual value is USD 339.38 M, beating the estimate of USD 327.89 M.

EPS: As of FY2027 Q1, the actual value is USD 0.72, missing the estimate of USD 0.7333.

EBIT: As of FY2027 Q1, the actual value is USD 57.46 M.

Total Revenue

Reported revenue for the first quarter of fiscal 2027 was $339.4 million, marking a 5.6% increase compared to the first quarter of fiscal 2026. Organic revenue growth for the quarter was 5.9% compared to the same period of fiscal 2026.

Segment Revenue (Reported)

• Apheresis: Revenue was $191.3 million, an increase of 5.3% year-over-year.
  • Plasma revenue reached $155.524 million, up 7.2%.
  • Other revenue was $35.794 million, representing a decrease of -2.4%.
• MedSurg: Revenue totaled $148.062 million, an increase of 6.0% year-over-year.
  • Interventional Technologies revenue was $59.942 million, up 2.5%.
  • Blood Management Technologies revenue amounted to $88.120 million, up 8.6%.

Segment Organic Revenue Growth

• Apheresis: Experienced 6.0% organic revenue growth.
• MedSurg: Experienced 5.9% organic revenue growth.

Gross Margin

GAAP gross margin was 59.8% in the first quarter of fiscal 2027, remaining flat compared to 59.8% in the first quarter of fiscal 2026. Adjusted gross margin was 60.4%, a decrease of -40 basis points compared to the prior year period.

Operating Expenses

GAAP operating expenses were $145.3 million, an increase of $7.0 million or 5.0% compared to the first quarter of fiscal 2026, driven by higher personnel-related costs and freight charges. Adjusted operating expenses were $125.6 million, an increase of $7.9 million or 6.7% compared to the first quarter of fiscal 2026, also due to higher personnel-related costs and freight charges.

Operating Income

GAAP operating income was $57.5 million, up 6.7% from $53.9 million in the first quarter of fiscal 2026. Adjusted operating income was $79.3 million, a decrease of -$1.7 million or -2.2% compared to the first quarter of fiscal 2026.

Operating Margin

GAAP operating margin was 16.9%, up 0.1% from 16.8% in the first quarter of fiscal 2026. Adjusted operating margin was 23.4%, down -70 basis points compared to the same period of fiscal 2026.

Net Income

GAAP net income was $33.0 million, a decrease of -3.0% from $34.0 million in the first quarter of fiscal 2026. Adjusted net income was $52.3 million, an increase of $0.9 million or 1.8% compared to the first quarter of fiscal 2026.

Effective Income Tax Rate

The GAAP effective income tax rate was 30.6% in the first quarter of fiscal 2027, compared to 24.7% in the first quarter of fiscal 2026. The adjusted income tax rate for the first quarter of fiscal 2027 was 25.7%, up 180 basis points from 24.9% in the prior year period.

Cash Flow

Cash flow from operating activities was $52.3 million, an increase of $34.9 million compared to $17.395 million in the first quarter of fiscal 2026. Free cash flow was $39.1 million, an increase of $36.6 million compared to $2.478 million in the first quarter of fiscal 2026.

Cash on Hand

Cash on hand as of June 27, 2026, was $223.4 million, a decrease of -$22.1 million since the end of fiscal 2026.

Fiscal 2027 Guidance

Haemonetics Corporation raised its fiscal 2027 GAAP revenue and organic revenue growth guidance, now expecting reported revenue growth of 5-8% and organic revenue growth of 4-7% for the full year. The company projects adjusted operating margin to expand by 50-100 basis points year-over-year. Free cash flow conversion is anticipated to be approximately 80%.